MLF2

Summary

MLF2 (myeloid leukemia factor 2, HGNC:7126) is a protein-coding gene on chromosome 12p13.31, encoding Myeloid leukemia factor 2 (Q15773).

Predicted to be involved in regulation of DNA-templated transcription. Located in membrane.

Source: NCBI Gene 8079 — RefSeq curated summary.

At a glance

• GWAS associations: 13
• Clinical variants (ClinVar): 141 total
• Druggable target: yes
• MANE Select transcript: NM_001382226

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7126
Approved symbol	MLF2
Name	myeloid leukemia factor 2
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Aliases	NTN4
Ensembl gene	ENSG00000089693
Ensembl biotype	protein_coding
OMIM	601401
Entrez	8079

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 18 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000203630, ENST00000435120, ENST00000536207, ENST00000536249, ENST00000537126, ENST00000539187, ENST00000540710, ENST00000541305, ENST00000541346, ENST00000564181, ENST00000888475, ENST00000888476, ENST00000888477, ENST00000888478, ENST00000888479, ENST00000888480, ENST00000888481, ENST00000932584, ENST00000932585, ENST00000932586, ENST00000963652, ENST00000963653

RefSeq mRNA: 3 — MANE Select: NM_001382226 NM_001382225, NM_001382226, NM_005439

CCDS: CCDS8559

Canonical transcript exons

ENST00000203630 — 9 exons

Exon	Start	End
ENSE00000715614	6750177	6750305
ENSE00000715615	6750713	6750766
ENSE00000866937	6748770	6748982
ENSE00002205662	6752939	6753141
ENSE00002293567	6747996	6748547
ENSE00003534196	6752285	6752362
ENSE00003581193	6749848	6750007
ENSE00003600283	6751641	6751676
ENSE00003681881	6751925	6752054

Expression profiles

Bgee: expression breadth ubiquitous, 292 present calls, max score 99.16.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 88.4063 / max 490.8687, expressed in 1826 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
129185	74.3491	1823
129186	14.0571	1805

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right frontal lobe	UBERON:0002810	99.16	gold quality
right hemisphere of cerebellum	UBERON:0014890	99.16	gold quality
cerebellar hemisphere	UBERON:0002245	99.13	gold quality
cerebellar cortex	UBERON:0002129	99.09	gold quality
prefrontal cortex	UBERON:0000451	98.99	gold quality
nucleus accumbens	UBERON:0001882	98.96	gold quality
right adrenal gland cortex	UBERON:0035827	98.88	gold quality
right adrenal gland	UBERON:0001233	98.82	gold quality
adenohypophysis	UBERON:0002196	98.82	gold quality
amygdala	UBERON:0001876	98.80	gold quality
metanephros cortex	UBERON:0010533	98.80	gold quality
caudate nucleus	UBERON:0001873	98.79	gold quality
left adrenal gland	UBERON:0001234	98.78	gold quality
left adrenal gland cortex	UBERON:0035825	98.77	gold quality
lower esophagus	UBERON:0013473	98.74	gold quality
lower esophagus muscularis layer	UBERON:0035833	98.74	gold quality
right lobe of liver	UBERON:0001114	98.73	gold quality
muscle layer of sigmoid colon	UBERON:0035805	98.72	gold quality
lower esophagus mucosa	UBERON:0035834	98.71	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	98.71	gold quality
body of uterus	UBERON:0009853	98.70	gold quality
putamen	UBERON:0001874	98.66	gold quality
cingulate cortex	UBERON:0003027	98.66	gold quality
left uterine tube	UBERON:0001303	98.63	gold quality
anterior cingulate cortex	UBERON:0009835	98.60	gold quality
adrenal cortex	UBERON:0001235	98.56	gold quality
cerebellum	UBERON:0002037	98.52	gold quality
Brodmann (1909) area 9	UBERON:0013540	98.52	gold quality
skin of leg	UBERON:0001511	98.49	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	98.47	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-6524	no	256.23
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BRD4, JMJD6

Literature-anchored findings (GeneRIF, showing 5)

• RPL39 and MLF2 have roles in tumor initiation and metastasis in breast cancer that involve nitric oxide synthase signaling (PMID:24876273)
• Mutation in HTT causes Huntington’s disease (HD); aggregates of mutated HTT cause apoptosis in neurons of HD patients. Data suggest that both MLF1 and MLF2 preferentially interact with mutated N-terminal HTT; MLF1/MLF2 reduce number of neurons (Neuro2A cell line) containing mutant HTT aggregates and subsequent apoptosis. (HTT = Huntingtin protein; MLF = myeloid leukemia factor) (PMID:27840155)
• The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis. (PMID:31831854)
• Torsin ATPase deficiency leads to defects in nuclear pore biogenesis and sequestration of MLF2. (PMID:32342107)
• CRL4(DCAF8) and USP11 oppositely regulate the stability of myeloid leukemia factors (MLFs). (PMID:32703400)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	mlf2	ENSDARG00000034616
mus_musculus	Mlf2	ENSMUSG00000030120
rattus_norvegicus	Mlf2	ENSRNOG00000016589
drosophila_melanogaster	Mlf	FBGN0034051
caenorhabditis_elegans		WBGENE00012468

Paralogs (1): MLF1 (ENSG00000178053)

Protein

Protein identifiers

Myeloid leukemia factor 2 — Q15773 (reviewed: Q15773)

Alternative names: Myelodysplasia-myeloid leukemia factor 2

All UniProt accessions (5): Q15773, F5H0Y3, F5H7L5, F5H800, Q5U0N1

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitously expressed.

Similarity. Belongs to the MLF family.

RefSeq proteins (3): NP_001369154, NP_001369155, NP_005430 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019376	Myeloid_leukemia_factor	Family

Pfam: PF10248

UniProt features (10 total): region of interest 3, modified residue 3, compositionally biased region 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q15773-F1	65.81	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 217, 238, 240

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 361 (showing top): GOBP_MORPHOGENESIS_OF_AN_EPITHELIUM, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_GLAND_MORPHOGENESIS, GOBP_REGULATION_OF_MORPHOGENESIS_OF_A_BRANCHING_STRUCTURE, GOBP_SALIVARY_GLAND_DEVELOPMENT, ENK_UV_RESPONSE_KERATINOCYTE_UP, GCANCTGNY_MYOD_Q6, GOBP_NEURON_MATURATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN, HSIAO_HOUSEKEEPING_GENES, GOBP_NEUROGENESIS, GOBP_EXTRACELLULAR_MATRIX_ASSEMBLY, CREBP1_Q2, GGGTGGRR_PAX4_03

GO Biological Process (1): regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), membrane (GO:0016020), glutamatergic synapse (GO:0098978), synapse (GO:0045202)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
synapse	1
cell junction	1

Protein interactions and networks

STRING

1056 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MLF2	ARFGAP2	Q8N6H7	735
MLF2	CROCC	Q5TZA2	705
MLF2	DOC2A	Q14183	649
MLF2	SCGN	O76038	629
MLF2	NPM1	P06748	592
MLF2	SNAP23	O00161	578
MLF2	RPL39	P02404	541
MLF2	KIF5B	P33176	533
MLF2	DNAJB6	O75190	518
MLF2	ARFGAP3	Q9NP61	469
MLF2	SGTA	O43765	442
MLF2	DDAH2	O95865	441
MLF2	HEMK2	Q9Y5N5	434
MLF2	CLEC14A	Q86T13	422
MLF2	HSP90AA1	P07900	411

IntAct

198 interactions, top by confidence:

A	B	Type	Score
HSPA8	BAG2	psi-mi:“MI:2364”(proximity)	0.860
MLF2	BAG2	psi-mi:“MI:0915”(physical association)	0.720
BAG2	MLF2	psi-mi:“MI:0915”(physical association)	0.720
HSPB8	MLF2	psi-mi:“MI:0915”(physical association)	0.680
DNAJC7	PLD2	psi-mi:“MI:0914”(association)	0.640
DNAJB6	MLF2	psi-mi:“MI:0915”(physical association)	0.630
MLF2	DNAJB6	psi-mi:“MI:0914”(association)	0.630
MLF2	STUB1	psi-mi:“MI:0915”(physical association)	0.620
BAG3	MLF2	psi-mi:“MI:0915”(physical association)	0.620
STUB1	MLF2	psi-mi:“MI:0915”(physical association)	0.620
MLF2	RAF1	psi-mi:“MI:0915”(physical association)	0.560
MLF2	DNAJC7	psi-mi:“MI:0915”(physical association)	0.560
EBNA-LP	HAX1	psi-mi:“MI:0914”(association)	0.530
L3MBTL1	DNAJB6	psi-mi:“MI:0914”(association)	0.530
HSPB8	VWA8	psi-mi:“MI:0914”(association)	0.530
BAG2	DNAJB6	psi-mi:“MI:0914”(association)	0.530
STUB1	DNAJB6	psi-mi:“MI:0914”(association)	0.530
BAG1	MLF2	psi-mi:“MI:0915”(physical association)	0.500
HSPA8	ARHGEF10	psi-mi:“MI:2364”(proximity)	0.480
AIFM1	HAX1	psi-mi:“MI:0914”(association)	0.420
CAT	NUDT19	psi-mi:“MI:0914”(association)	0.420
TUBA1A	TUBAL3	psi-mi:“MI:0914”(association)	0.420
MLF2	EIF2C2	psi-mi:“MI:0915”(physical association)	0.400
MLF2	MLF1	psi-mi:“MI:0915”(physical association)	0.400
MLF2		psi-mi:“MI:0915”(physical association)	0.400
MLF2	PSMC4	psi-mi:“MI:0915”(physical association)	0.400
MLF2	HAX1	psi-mi:“MI:0915”(physical association)	0.400
MLF2	IRS4	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (193): MLF2 (Affinity Capture-RNA), MLF2 (Affinity Capture-RNA), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Two-hybrid), MLF2 (Synthetic Lethality), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-MS), MLF2 (Affinity Capture-Western), MLF2 (Proximity Label-MS)

ESM2 similar proteins: A0A804C8T0, A4ZNR4, A4ZNR5, B2RX88, F7C1E2, O00165, O08623, O35387, O70367, O75829, O77770, P17404, P25686, P58340, Q03157, Q08E24, Q13501, Q15773, Q16626, Q29407, Q2KIE2, Q32KY3, Q3UIL6, Q4R992, Q5R491, Q5R4T3, Q5RBA5, Q5XIA0, Q64337, Q6AYN2, Q6BEG7, Q6IQ23, Q6PAQ9, Q7TNY7, Q7TSE9, Q7Z5B4, Q8BK03, Q8BPM6, Q8K3I4, Q8NFW9

Diamond homologs: P58340, Q15773, Q32KY3, Q5R4T3, Q99KX1, Q9NKV0, Q9QWV4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 191 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Cellular response to heat stress	6	17.8×	7e-05
Activation of AMPK downstream of NMDARs	5	14.3×	4e-04
Autodegradation of the E3 ubiquitin ligase COP1	7	14.0×	6e-05
Orc1 removal from chromatin	10	13.4×	9e-07
The role of GTSE1 in G2/M progression after G2 checkpoint	11	13.3×	4e-07
AUF1 (hnRNP D0) binds and destabilizes mRNA	7	13.1×	7e-05
Sealing of the nuclear envelope (NE) by ESCRT-III	5	13.0×	5e-04
Regulation of activated PAK-2p34 by proteasome mediated degradation	6	12.6×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
protein folding	10	6.3×	3e-03
proteasome-mediated ubiquitin-dependent protein catabolic process	14	4.5×	3e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

141 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	107
Likely benign	8
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1765 predictions. Top by Δscore:

Variant	Effect	Δscore
12:6748900:AAG:A	donor_gain	1.0000
12:6748978:CTCAC:C	acceptor_gain	1.0000
12:6748979:TCAC:T	acceptor_gain	1.0000
12:6748980:CAC:C	acceptor_gain	1.0000
12:6748980:CACC:C	acceptor_gain	1.0000
12:6748981:ACCT:A	acceptor_loss	1.0000
12:6748983:C:CC	acceptor_gain	1.0000
12:6748983:C:CG	acceptor_loss	1.0000
12:6749117:C:A	donor_gain	1.0000
12:6749123:G:C	donor_gain	1.0000
12:6749842:GCTCA:G	donor_loss	1.0000
12:6749843:CTCA:C	donor_loss	1.0000
12:6749844:TCA:T	donor_loss	1.0000
12:6749845:CACTC:C	donor_loss	1.0000
12:6749846:A:AC	donor_gain	1.0000
12:6749846:ACTCT:A	donor_gain	1.0000
12:6749847:C:CT	donor_gain	1.0000
12:6749847:CT:C	donor_gain	1.0000
12:6749847:CTCT:C	donor_gain	1.0000
12:6749847:CTCTC:C	donor_gain	1.0000
12:6749850:T:A	donor_gain	1.0000
12:6749852:AT:A	donor_gain	1.0000
12:6749853:T:C	donor_gain	1.0000
12:6749853:T:TA	donor_gain	1.0000
12:6749864:ATAGT:A	donor_gain	1.0000
12:6749866:AGT:A	donor_gain	1.0000
12:6749868:T:TA	donor_gain	1.0000
12:6749880:T:TA	donor_gain	1.0000
12:6750003:CGGAT:C	acceptor_gain	1.0000
12:6750004:GGAT:G	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000489870 (12:6751250 C>G), RS1000602339 (12:6754383 T>A), RS1000866966 (12:6754814 G>T), RS1001059298 (12:6754045 A>G), RS1001363157 (12:6755097 A>G), RS1002809669 (12:6752553 T>C,G), RS1002947001 (12:6752773 C>G,T), RS1004442645 (12:6753160 C>G,T), RS1004586097 (12:6755104 G>A), RS1004656052 (12:6747681 G>C), RS1004836543 (12:6751851 G>A,C), RS1004908845 (12:6753056 C>A,T), RS1005169741 (12:6752154 G>A), RS1005296476 (12:6749076 G>A,C,T), RS1005471992 (12:6753997 G>C)

Disease associations

OMIM: gene MIM:601401 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST001930_10	Breast cancer	9.000000e-06
GCST001937_18	Breast cancer	2.000000e-22
GCST002108_1	Allergic dermatitis (nickel)	4.000000e-06
GCST003985_1	Breast size	1.000000e-13
GCST004988_45	Breast cancer	1.000000e-39
GCST006585_1	Blood protein levels	2.000000e-12
GCST006627_17	Diastolic blood pressure	2.000000e-10
GCST006719_11	BRCA1/2-negative high-risk breast cancer	9.000000e-07
GCST007637_21	Diffusing capacity of carbon monoxide	2.000000e-06
GCST007673_8	3-month functional outcome in ischaemic stroke (modified Rankin score)	1.000000e-06
GCST008522_63	Bitter alcoholic beverage consumption	1.000000e-06
GCST010002_220	Refractive error	1.000000e-19
GCST010242_89	HDL cholesterol levels	3.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0006336	diastolic blood pressure
EFO:0009443	BRCAX breast cancer
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0009603	stroke outcome severity measurement
EFO:0010092	bitter alcoholic beverage consumption measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4295830 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

39 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression	2
Cyclosporine	decreases expression	2
FR900359	affects phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
JP8 aviation fuel	decreases expression	1
nutlin 3	affects cotreatment, increases expression, increases secretion	1
jinfukang	affects cotreatment, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Aspirin	decreases expression	1
Caffeine	affects phosphorylation	1
Cisplatin	affects cotreatment, increases expression	1
Dactinomycin	affects cotreatment, increases expression, increases secretion	1
Dexamethasone	affects cotreatment, increases expression	1
Diazinon	increases methylation	1
Endosulfan	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Flavonoids	increases expression	1
Formaldehyde	increases expression	1
Gasoline	affects cotreatment, increases abundance, increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methyl Methanesulfonate	increases expression	1
Ozone	affects expression, increases abundance	1
Plant Extracts	increases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, increases abundance, increases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4118719	Binding	Binding affinity to MLF2 in human NCI-H23 cells at 1 uM by mass spectrometry based pull down assay	Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors. — Bioorg Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer